Diabetes Guidelines May Delay Timely Adjustments During Treatment and Might Contribute to Clinical Inertia
| dc.contributor.author | Pimazoni-Netto, Augusto [UNIFESP] | |
| dc.contributor.author | Zanella, Maria Teresa [UNIFESP] | |
| dc.contributor.institution | Universidade Federal de São Paulo (UNIFESP) | |
| dc.date.accessioned | 2016-01-24T14:38:02Z | |
| dc.date.available | 2016-01-24T14:38:02Z | |
| dc.date.issued | 2014-11-01 | |
| dc.description.abstract | Clinical inertia and poor knowledge by many physicians play an important role in delaying diabetes control. Among other guidelines, the Position Statement of the American Diabetes Association/European Association for the Study of Diabetes on Management of Hyperglycemia in Type 2 Diabetes is a respected guideline with high impact on this subject in terms of influencing physicians in the definition of strategic approach to overcome poor glycemic control. But, on the other hand, it carries a recommendation that might contribute to clinical inertia because it can delay the needed implementation of more vigorous, intensive, and effective strategies to overcome poor glycemic control within a reasonable time frame during the evolution of the disease. the same is true with other respected algorithms from different diabetes associations. Together with pharmacological interventions, diabetes education and more intensive blood glucose monitoring in the initial phases after the diagnosis are key strategies for the effective control of diabetes. the main reason why a faster glycemic control should be implemented in an effective and safe way is to boost the confidence and the compliance of the patient to the recommendations of the diabetes care team. Better and faster results in glycemic control can only be safely achieved with educational strategies, structured self-monitoring of blood glucose, and adequate pharmacological therapy in the majority of cases. | en |
| dc.description.affiliation | Universidade Federal de São Paulo, Kidney & Hypertens Hosp, Diabet Educ & Control Grp, São Paulo, Brazil | |
| dc.description.affiliation | Universidade Federal de São Paulo, Kidney & Hypertens Hosp, Dept Endocrinol, São Paulo, Brazil | |
| dc.description.affiliationUnifesp | Universidade Federal de São Paulo, Kidney & Hypertens Hosp, Diabet Educ & Control Grp, São Paulo, Brazil | |
| dc.description.affiliationUnifesp | Universidade Federal de São Paulo, Kidney & Hypertens Hosp, Dept Endocrinol, São Paulo, Brazil | |
| dc.description.source | Web of Science | |
| dc.format.extent | 768-770 | |
| dc.identifier | http://dx.doi.org/10.1089/dia.2014.0092 | |
| dc.identifier.citation | Diabetes Technology & Therapeutics. New Rochelle: Mary Ann Liebert, Inc, v. 16, n. 11, p. 768-770, 2014. | |
| dc.identifier.doi | 10.1089/dia.2014.0092 | |
| dc.identifier.issn | 1520-9156 | |
| dc.identifier.uri | http://repositorio.unifesp.br/handle/11600/38356 | |
| dc.identifier.wos | WOS:000343419900011 | |
| dc.language.iso | eng | |
| dc.publisher | Mary Ann Liebert, Inc | |
| dc.relation.ispartof | Diabetes Technology & Therapeutics | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.title | Diabetes Guidelines May Delay Timely Adjustments During Treatment and Might Contribute to Clinical Inertia | en |
| dc.type | info:eu-repo/semantics/article |